Milestones in the Development of Rituximab
An article on targeted therapy for B-cell lymphoma by Ronald D. Levy, MD, David G. Maloney, MD, PhD, and Richard Miller, MD, and these accompanying milestones were published in December 2008 as part of the special ASH anniversary brochure, 50 Years in Hematology: Research That Revolutionized Patient Care.
| Mid- 1970s |
Monoclonal antibodies are developed by Georges J.F. Köhler and César Milstein to fight cancer. Their technique allows a specific antibody molecule to be produced in unlimited quantities. |
| 1982 | The first successful treatment of a cancer patient with a monoclonal antibody takes place. |
| 1993 | For the first time, rituximab is used to treat lymphoma. |
| 1997 | The U.S. Food and Drug Administration (FDA) approves rituximab for the treatment of lymphoma. |
| 2008 | Nine monoclonal antibodies are approved by the FDA for the treatment of various cancers. |
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission